secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208965
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall
--------------------------------------------------------------------------------

- Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
- Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.
- Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.
- Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.
- Management expects return to procedure growth in second half of 2026 after recall impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/0001193125-26-208965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312526208965/btmd-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer